Cargando…

Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: a single center experience.

Detalles Bibliográficos
Autores principales:	Xue, Elisabetta, Scorpio, Gianluca, Ruggeri, Annalisa, Clerici, Daniela, Farina, Francesca, Campodonico, Edoardo, Acerbis, Andrea, Fiore, Paolo, Bruno, Alessandro, Carrabba, Matteo G, Peccatori, Jacopo, Greco, Raffaella, Stanghellini, Maria Teresa Lupo, Ciceri, Fabio, Corti, Consuelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299847/ https://www.ncbi.nlm.nih.gov/pubmed/37399601 http://dx.doi.org/10.1016/j.retram.2023.103402

Ejemplares similares

Following-up allogeneic transplantation recipients during the COVID-19 pandemic
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2020)

Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2021)

PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
por: Diral, Elisa, et al.
Publicado: (2023)

Lung Ultrasound to Evaluate Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation
por: Raffaella, Greco, et al.
Publicado: (2019)

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study
por: Xue, Elisabetta, et al.
Publicado: (2022)

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial
por: Lazzari, Lorenzo, et al.
Publicado: (2021)

Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis
por: Ardizzoia, Federica, et al.
Publicado: (2022)

Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
por: Noviello, Maddalena, et al.
Publicado: (2023)

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
por: Giglio, Fabio, et al.
Publicado: (2023)

COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
por: Dichtl, Stefanie, et al.
Publicado: (2022)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
por: Shimizu, Takahiro, et al.
Publicado: (2023)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections
por: Oltolini, Chiara, et al.
Publicado: (2018)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome
por: Greco, Raffaella, et al.
Publicado: (2021)

Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation
por: Tassi, Elena, et al.
Publicado: (2022)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia
por: Oltolini, Chiara, et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
por: Maselkar, Sheetal, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
por: Dluzynski, Daniela, et al.
Publicado: (2023)

Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients
por: Serpenti, Fabio, et al.
Publicado: (2021)

P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
por: Farina, Francesca, et al.
Publicado: (2023)

Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients
por: Mancini, Nicasio, et al.
Publicado: (2017)

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.
por: Sannipoli, Daniele, et al.
Publicado: (2023)

INCIDENCE OF COVID-19 INFECTIONS IN ADULTS WITH PRIMARY IMMUNODEFICIENCY AFTER RECEIVING TIXAGEVIMAB AND CILGAVIMAB
por: Johnson, S., et al.
Publicado: (2022)

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases
por: Otiniano, Armelle, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
por: Miot, Christelle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ke8maiodbhpq5ou0jj80krmufc